Refining prognosis in BCR-ABL1 - Positive ALL

Blood

Volumn 123, Issue 11, 2014, Pages 1626-1627

  Raetz, Elizabeth A ^a,b   Carroll, William L ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IKAROS TRANSCRIPTION FACTOR; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR IKZF1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; EXON; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; NOTE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; WILD TYPE;

CHROMOSOME ABERRATIONS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IKAROS TRANSCRIPTION FACTOR; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84897481699     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-547570     Document Type: Note

References (10)

1. van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1 - positive childhood ALL. Blood. 2014;123(11):1691-1698.
2. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936-945.
3. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
4. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10):2159-2167.
5. Mullighan CG, Su X, Zhang J, et al Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
6. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202-5207.
7. Li Z, Perez-Casellas LA, Savic A, Song C, Dovat S. Ikaros isoforms: the saga continues. World J Biol Chem. 2011;2(6):140-145.
8. Palmi C, Valsecchi MG, Longinotti G, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica. 2013;98(8):1226-1231.
9. Uckun FM, Ma H, Ishkhanian R, et al. Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. PLoS ONE. 2013;8(11):e80732.
10. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622- 2629.